Online solid-phase extraction liquid chromatography-electrospray-tandem mass spectrometry analysis of buprenorphine and three metabolites in human urine

被引:31
作者
Liu, An-Chan [1 ]
Lin, Tzuen-Yeuan [1 ]
Su, Lien-Wen [2 ]
Fuh, Ming-Ren [1 ]
机构
[1] Soochow Univ, Dept Chem, Taipei, Taiwan
[2] Taipei City Hosp, Dept Addict Sci, Taipei City Psychiat Ctr, Taipei, Taiwan
关键词
buprenorphine; urine analysis; online solid-phase extraction; liquid chromatography-electrospray-tandem mass spectrometry;
D O I
10.1016/j.talanta.2007.10.050
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
An online solid-phase extraction (SPE) liquid chromatography-electrospray tandem mass spectrometry (LC-ESI-MSIMS) method for the determination of buprenorphine (Bup), norbuprenorphine (nBup), buprenorphie-3-beta-D-glucuronide (Bup-3-G) and norbuprenorphie-3-beta-D-glucuronide (nBup-3-G) in human urine was developed and validated. A mixed mode SPE column with both hydrophilic and lipophilic functions was used for online extraction. A C-18 column was employed for LC separation and ESI-MS/MS was utilized for detection. Buprenorphine-D-4 (Bup-D-4) and norbuprenophine-D-3 (nBup-D-3) were used as internal standards for quantitative determination. The extraction, clean-up and analysis procedures were controlled by a fully automated six-port switch valve. Identification and quantification were based on the following transitions: m/z 468 -> 414 for Bup, m/z 414 -> 364 for nBup, m/z 644 -> 468 for Bup-3-G and m/z 590 -> 414 for nBup-3-G, respectively. Good recoveries from 93.6% to 102.2% were measured and satisfactory linear ranges for these analytical compounds were determined. Minimal ion suppression effect (similar to 7% response decrease) was determined. Intra-day and inter-day precision showed coefficients of variance, CV, ranged from 3.3% to 10.1% and 4.4% to 9.8%, respectively. Accuracy ranging from 97.0% to 104.0% was determined. The applicability of this newly developed method was demonstrated by analyzing human urine samples from the patients in Bup treatment program for therapeutic monitoring purpose. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:198 / 204
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 1995, DISPOSITION TOXIC DR
[2]   Quantitation of SR 27417 in human plasma using electrospray liquid chromatography tandem mass spectrometry: A study of ion suppression [J].
Buhrman, DL ;
Price, PI ;
Rudewicz, PJ .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 1996, 7 (11) :1099-1105
[3]   Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry [J].
Ceccato, A ;
Klinkenberg, R ;
Hubert, P ;
Streel, B .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 32 (4-5) :619-631
[4]   Pharmacokinetics of the combination tablet of buprenorphine and naloxone [J].
Chiang, CN ;
Hawks, RL .
DRUG AND ALCOHOL DEPENDENCE, 2003, 70 :S39-S47
[5]  
CONE EJ, 1984, DRUG METAB DISPOS, V12, P577
[6]   Bluprenorphine - Clinical pharmacokinetics in the treatment of opioid dependence [J].
Elkader, A ;
Sproule, B .
CLINICAL PHARMACOKINETICS, 2005, 44 (07) :661-680
[7]   Potentials of ion trap collisional spectrometry for liquid chromatography/electrospray ionization tandem mass spectrometry determination of buprenorphine and nor-buprenorphine in urine, blood and hair samples [J].
Favretto, D ;
Frison, G ;
Vogliardi, S ;
Ferrara, SD .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2006, 20 (08) :1257-1265
[8]   Determination of flunitrazepam and 7-aminoflunitrazepam in human urine by on-line solid phase extraction liquid chromatography-electrospray-tandem mass spectrometry [J].
Fuh, Ming-Ren ;
Lin, Shi-Wei ;
Chen, Li-Lung ;
Lin, Tzuen-Yeuan .
TALANTA, 2007, 72 (04) :1329-1335
[9]   Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma [J].
Gopal, S ;
Tzeng, TB ;
Cowan, A .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2001, 51 (02) :147-151
[10]  
JANSINSKI D, 1978, ARCH GEN PSYCHIAT, V34, P501